Research Progress on Furmonertinib in Treatment of Non-Small Cell Lung Cancer
Non-small cell lung cancer(NSCLC)accounts for 80％～85％of lung cancer cases,and epidermal growth factor receptor(EGFR)gene mutations are the most common driver mutations in NSCLC.EGFR-tyrosine kinase in-hibitors(EGFR-TKI)have been the standard first-line treatment for advanced NSCLC with EGFR-sensitive mutations.Furmonertinib is a third-generation EGFR-TKI developed in China,characterized by dual activity,high selectivity,strong tumor shrinkage effects and good safety.Furmonertinib has demonstrated definite efficacy in the treatment of NSCLC with EGFR T790M mutation,EGFR-sensitive mutation,EGFR exon 20 insertion mutation and central ner-vous system metastasis.Meanwhile,exploration and research on perioperative treatment and rechallenge with fur-monertinib after resistance to third-generation EGFR-TKI are also increasingly prevalent.This paper reviews the progress and clinical studies on the use of furmonertinib in the treatment of EGFR-mutated NSCLC to provide refe-rence for its clinical application.
NETL
NSTL
万方数据
